Literature DB >> 1382324

Dimethylnitrosamine (DMN)-induced IL-1 beta, TNF-alpha, and IL-6 inflammatory cytokine expression.

L B Schook1, J F Lockwood, S D Yang, M J Myers.   

Abstract

Altered immune functions have been demonstrated in mice following exposure to dimethylnitrosamine (DMN). In particular, changes in cell-mediated immune responses resulted from chronic DMN exposure in vivo. Since cytokines are potent immunoregulatory peptides, experiments were performed to determine whether DMN exposure results in the induction of serum-borne inflammatory cytokines. Animals were exposed to either vehicle (PBS) or DMN (5.0 mg/kg) every 24 hr for 14 days. Serum and liver samples were obtained from individual mice at 0, 1, 2, 3, 6, 12, and 24 hr following the first exposure, with additional samples collected every 24 hr preceding the daily DMN exposure. Sera were then analyzed for IL-1 beta, IL-3, IL-6, CSF-1, GM-CSF, and TNF-alpha activities using either biological or immunological assays. In addition, liver total cellular RNA was probed for the induction of IL-1 beta transcripts using the solution hybridization/RNase protection assay. IL-1 beta, IL-6, and TNF-alpha serum activities were observed within 2 hr of DMN exposure and returned to vehicle control levels by 3 days even though DMN exposure was maintained. Chronic expression of cytokine activity (after 72 hr) was only observed for GM-CSF. A rapid induction of IL-1 beta transcripts (within 1 hr) in both vehicle and DMN-treated animals was observed by solution hybridization. However, by 3 hr postexposure, transcript levels decreased in the vehicle-treated animals while remaining elevated in the DMN-treated animals for 6 hr. These results demonstrated that DMN exposure in vivo induced: (1) the expression of serum-borne cytokine activities, and (2) IL-1 beta transcription in liver tissue.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382324     DOI: 10.1016/0041-008x(92)90151-h

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  3 in total

1.  Monocytes of individual human subjects display heterogeneous bacterial uptake and antilisterial activity.

Authors:  G Zerlauth; H E Chehadeh; E Maier; Z Schaff; M M Eibl; J W Mannhalter
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

Review 2.  Brain metabolic dysfunction at the core of Alzheimer's disease.

Authors:  Suzanne M de la Monte; Ming Tong
Journal:  Biochem Pharmacol       Date:  2013-12-28       Impact factor: 5.858

3.  SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis.

Authors:  Takafumi Yoshida; Hisanobu Ogata; Masaki Kamio; Akiko Joo; Hiroshi Shiraishi; Yoko Tokunaga; Michio Sata; Hisaki Nagai; Akihiko Yoshimura
Journal:  J Exp Med       Date:  2004-06-14       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.